GLP-1 Receptor in Pancreatic α-Cells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner
Open accessThe DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 (GLP-1) is known to suppress glucagon secretion, but the mechanism by which GLP-1 exerts this effect is unclear. In this study, we demonstrated GLP-1 receptor (GLP-1R) expression in α-cells using both antibody-dependent and antibody-independent strategies. A novel α-cell–specific GLP-1R knockout (αGLP-1R−/−) mouse model was created and used to investigate its effects on glucagon secretion and glucose metabolism. Male and female αGLP-1R−/− mice both showed higher nonfasting glucagon levels than their wild-type littermates, whereas insulin and GLP-1 levels remained similar. Female αGLP-1R−/− mice exhibited mild glucose intolerance after an intraperitoneal glucose administration and showed increased glucagon secretion in response to a glucose injection compared with the wild-type animals. Furthermore, using isolated islets, we confirmed that αGLP-1R deletion did not interfere with β-cell function but affected glucagon secretion in a glucose-dependent bidirectional manner: the αGLP-1R−/− islets failed to inhibit glucagon secretion at high glucose and failed to stimulate glucagon secretion at very low glucose condition. More interestingly, the same phenomenon was recapitulated in vivo under hypoglycemic and postprandial (fed) conditions. Taken together, this study demonstrates that GLP-1 (via GLP-1R in α-cells) plays a bidirectional role, either stimulatory or inhibitory, in glucagon secretion depending on glucose levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 also inhibits glucagon release from α-cells, which is beneficial for reducing blood glucose levels since glucagon promotes hepatic gluconeogenesis.131,225”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Research indicates that the expression level of GLP-1R on α-cells is relatively low.131”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [131]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adult insulin- and glucagon-producing cells differentiate from two independent cell lineages
Herrera, P. L. (2000) · Development · doi:10.1242/dev.127.11.2317 · Cited by 672
α-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains
Gromada, J., Franklin, I., & Wollheim, C. B. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0007 · Cited by 581 · cited 1×
“Under normal conditions, glucagon secretion is highly responsive to glucose variations: glucagon secretion is minimal when the glucose level is 6–10 mmol/L, increases when glucose is 3–6 mmol/L, and is maximally stimulated when glucose is 2–3 mmol/L (31).”
BackgroundRichards, P., Parker, H. E., Adriaenssens, A. E., Hodgson, J. M., Cork, S. C., Trapp, S., Gribble, F. M., & Reimann, F. (2014) · Diabetes · doi:10.2337/db13-1440 · Cited by 472 · cited 4×
“The controversy on GLP-1R expression in a-cells was largely attributable to the use of different antibodies or different methods (7,8,10,30).”
BackgroundMethodInfluentialNauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429
ØRSKOV, C., HOLST, J. J., & NIELSEN, O. V. (1988) · Endocrinology · doi:10.1210/endo-123-4-2009 · Cited by 396 · cited 1×
“However, this indirect hypothesis cannot explain the facts that the glucagonostatic effect of GLP-1 is present even when insulin is unstimulated (15,16) or in patients with type 1 diabetes with no residual b-cells (17,18).”
BackgroundPanjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao, X., Baggio, L. L., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1937 · Cited by 346 · cited 3×
“To make the topic even more complicated, studies have reported that the commonly used anti–GLP1R antibodies are neither specific nor sensitive enough to reliably detect GLP-1R expression in tissues (1,12).”
BackgroundCreutzfeldt, W. O. C., Kleine, N., Willms, B., Ørskov, C., Holst, J. J., & Nauck, M. A. (1996) · Diabetes Care · doi:10.2337/diacare.19.6.580 · Cited by 330 · cited 2×
“However, this indirect hypothesis cannot explain the facts that the glucagonostatic effect of GLP-1 is present even when insulin is unstimulated (15,16) or in patients with type 1 diabetes with no residual b-cells (17,18).”
BackgroundResultIncretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls
Drucker, D. J. (2013) · Diabetes · doi:10.2337/db13-0822 · Cited by 272 · cited 4×
“To make the topic even more complicated, studies have reported that the commonly used anti–GLP1R antibodies are neither specific nor sensitive enough to reliably detect GLP-1R expression in tissues (1,12).”
BackgroundInfluentialAlpha cell function in health and disease: influence of glucagon-like peptide-1
Dunning, B. E., Foley, J. E., & Ahrén, B. (2005) · Diabetologia · doi:10.1007/s00125-005-1878-0 · Cited by 271 · cited 1×
“Numerous studies have demonstrated that GLP-1 is a potent and physiological inhibitor of glucagon secretion (5,6).”
BackgroundParacrinology of islets and the paracrinopathy of diabetes
Unger, R. H., & Orci, L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006639107 · Cited by 269 · cited 1×
“insulin—GLP-1 stimulates insulin secretion from b-cells, which subsequently suppress glucagon secretion because insulin is a powerful inhibitor of glucagon secretion (13,14).”
Background
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“131,225 GLP-1 ’ s action on α -cells regulates glucagon release.”
BackgroundInfluentialRevisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289
“13 reporter mouse line, detected GLP-1R throughout the -cell and α-cell cytoplasm (45).”
BackgroundIncretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
Alicic, R. Z., Cox, E. J., Neumiller, J. J., & Tuttle, K. R. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00367-2 · Cited by 193
Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., Gupta, D., & Edison, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101979 · Cited by 179
“Regulation of glucagon secretion by pancreatic α -cells β cells whilst increasing insulin biosynthesis and pancreatic β cell proliferation, in a glucose-dependent manner, are additional effects of this drug class shown in rodents (Zhang et al., 2019).”
BackgroundRevisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases
Hædersdal, S., Andersen, A., Knop, F. K., & Vilsbøll, T. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00817-4 · Cited by 176
Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179583 · Cited by 148
Yoshinari, Y., Kosakamoto, H., Kamiyama, T., Hoshino, R., Matsuoka, R., Kondo, S., Tanimoto, H., Nakamura, A., Obata, F., & Niwa, R. (2021) · Nature Communications · doi:10.1038/s41467-021-25146-w · Cited by 158
Kloock, S., Ziegler, C. G., & Dischinger, U. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108549 · Cited by 197
Ast, J., Arvaniti, A., Fine, N. H. F., Nasteska, D., Ashford, F. B., Stamataki, Z., Koszegi, Z., Bacon, A., Jones, B. J., Lucey, M. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14309-w · Cited by 140
Min, J. S., Jo, S. J., Lee, S., Kim, D. Y., Kim, D. H., Lee, C. B., & Bae, S. K. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s506957 · Cited by 132
“11 Abbreviations : hGLP-1, human glucagon-like peptide-1; DPP-4, dipeptidyl peptidase-4; IgG4-Fc, immunoglobulin G4 fragment crystallizable; Aib, α -aminoisobutyric acid; OEG, oligoethylene glycol; hGIP, human glucose-dependent insulinotropic polypeptide.”
Buenaventura, T., Bitsi, S., Laughlin, W. E., Burgoyne, T., Lyu, Z., Oqua, A. I., Norman, H., McGlone, E. R., Klymchenko, A. S., Corrêa, I. R., et al. (2019) · PLOS Biology · doi:10.1371/journal.pbio.3000097 · Cited by 94
Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress
Diz-Chaves, Y., Herrera-Pérez, S., González-Matías, L. C., Lamas, J. A., & Mallo, F. (2020) · Nutrients · doi:10.3390/nu12113304 · Cited by 84
Pechenov, S., Revell, J., Will, S., Naylor, J., Tyagi, P., Patel, C., Liang, L., Tseng, L., Huang, Y., Rosenbaum, A. I., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-01750-0 · Cited by 77
Pancreatic α-cells – The unsung heroes in islet function
Wendt, A., & Eliasson, L. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.01.006 · Cited by 87
Recent advances in understanding the role of glucagon-like peptide 1
Reed, J., Bain, S., & Kanamarlapudi, V. (2020) · F1000Research · doi:10.12688/f1000research.20602.1 · Cited by 66
The β Cell in Diabetes: Integrating Biomarkers With Functional Measures
Kahn, S. E., Chen, Y., Esser, N., Taylor, A. J., van Raalte, D. H., Zraika, S., & Verchere, C. B. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab021 · Cited by 80
Emerging diabetes therapies: Bringing back the β-cells
Basile, G., Qadir, M. M. F., Mauvais‐Jarvis, F., Vetere, A., Shoba, V. M., Modell, A. E., Pastori, R. L., Russ, H. A., Wagner, B. K., & Domínguez‐Bendala, J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101477 · Cited by 62
Self-citationKarakasis, P., Fragakis, N., Patoulias, D., Theofilis, P., Kassimis, G., Karamitsos, T. D., El‐Tanani, M., & Rizzo, M. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02959-x · Cited by 65
“Of note, GLP‑1 receptor agonists can enhance myocardial energy metab‑ olism by modifying myocardial fatty acid metab‑ olism, stabilizing blood glucose levels [33], and regulating myocardial mitochondrial function through the renin–angiotensin–aldosterone sys‑ tem [34].”
Fiorentino, T. V., Casiraghi, F., Davalli, A. M., Finzi, G., La Rosa, S., Higgins, P. B., Abrahamian, G. A., Marando, A., Sessa, F., Perego, C., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.93091 · Cited by 51
Human Pluripotent Stem Cells to Model Islet Defects in Diabetes
Balboa, D., Iworima, D. G., & Kieffer, T. J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.642152 · Cited by 45
Structural pharmacology and mechanisms of GLP-1R signaling
Zhou, Q., Zhao, F., Zhang, Y., Yang, D., & Wang, M. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.03.003 · Cited by 52
Self-citationPeptides in the regulation of glucagon secretion
Andersen, D. B., & Holst, J. J. (2022) · Peptides · doi:10.1016/j.peptides.2021.170683 · Cited by 43
“Only few studies find appreciable expression of GLP-1R on α-cells [174], and most often it is either not”
Emerging Roles of Small GTPases in Islet β-Cell Function
Veluthakal, R., & Thurmond, D. C. (2021) · Cells · doi:10.3390/cells10061503 · Cited by 47
Discordance between GLP-1R gene and protein expression in mouse pancreatic islet cells
Gray, S. M., Xin, Y., Ross, E. C., Chazotte, B. M., Capozzi, M. E., El, K., Svendsen, B., Ravn, P., Sloop, K. W., Tong, J., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.014368 · Cited by 38
Self-citationvan den Broek, M., de Heide, L. J. M., Sips, F. L. P., Koehorst, M., van Zutphen, T., Emous, M., van Faassen, M. H. J. R., Groen, A. K., van Riel, N. A. W., de Boer, J. F., et al. (2021) · International Journal of Obesity · doi:10.1038/s41366-020-00726-w · Cited by 40
Glucagon‐Like Peptide‐1: Actions and Influence on Pancreatic Hormone Function
Davis, E., & Sandoval, D. A. (2020) · Comprehensive physiology · doi:10.1002/cphy.c190025 · Cited by 59
Evidence for the existence and potential roles of intra-islet glucagon-like peptide-1
Campbell, S. A., Johnson, J., & Light, P. E. (2021) · Islets · doi:10.1080/19382014.2021.1889941 · Cited by 42
Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets
Folli, F. B., Finzi, G., Manfrini, R., Galli, A., Casiraghi, F., Centofanti, L., Berra, C., Fiorina, P., Davalli, A. M., Rosa, S. L., et al. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00236.2023 · Cited by 35
Gandasi, N. R., Gao, R., Kothegala, L., Pearce, A., Santos, C., Acreman, S., Basco, D., Benrick, A., Chibalina, M. V., Clark, A., et al. (2024) · Diabetologia · doi:10.1007/s00125-023-06060-w · Cited by 31
GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation
Zhong, J., Chen, H., Liu, Q., Zhou, S., Liu, Z., & Xiao, Y. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.12.007 · Cited by 36
“GLP-1 RAs can improve myocardial energy metabolism, including modifying myocardial FA metabolism, stabilizing blood glucose levels [73], and regulating myocardial mitochondrial function through RAAS regulation [74].”
BackgroundRamírez-Mejía, M. M., Ponciano‐Rodríguez, G., Eslam, M., & Méndez-Sánchez, N. (2025) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188251406456 · Cited by 44
“33 When GLP-1 binds to its receptor on alpha cells, it triggers intracellular signaling pathways that increase cAMP levels, initiating processes that suppress glucagon synthesis and release.”
Repositioning the Alpha Cell in Postprandial Metabolism
EL, K. M., Capozzi, M. E., & Campbell, J. E. (2020) · Endocrinology · doi:10.1210/endocr/bqaa169 · Cited by 37
Ren, L., Cui, Q., Liu, W., Wang, L., Liao, Y., Feng, Y., Sun, W., Yang, Y., Zhang, Z., Jin, T., et al. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00930 · Cited by 30
“…to see that under in vitro conditions GLP-1 not only enhances insulin secretion, but also stimulates glucagon release by activation of GLP-1 receptor mediated signaling pathway involving protein kinase A and opening the voltage-dependent Ca2+ channels (Ding et al., 1997; Zhang et al., 2019).”
BackgroundAltered islet prohormone processing: a cause or consequence of diabetes?
Ramzy, A., & Kieffer, T. J. (2021) · Physiological Reviews · doi:10.1152/physrev.00008.2021 · Cited by 32
Kim, S. H., Abbasi, F., Nachmanoff, C., Stefanakis, K., Kumar, A., Kalra, B., Savjani, G. V., & Mantzoros, C. S. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14242 · Cited by 50
Activation of Insulin Signaling by Botanical Products
Rosenzweig, T., & Sampson, S. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084193 · Cited by 32
“GLP-1 is a hormone secreted by entero-endocrine L cells in response to glucose absorption, and suppresses glucagon secretion from α cells while it promotes expansion of β cell mass and potentiates insulin secretion [3,4].”
BackgroundAhmad, P., Estrin, N. E., Farshidfar, N., Zhang, Y., & Miron, R. J. (2025) · Journal of Periodontal Research · doi:10.1111/jre.13410 · Cited by 32
Self-citationStimulus-Secretion Coupling in Beta-Cells: From Basic to Bedside
Islam, M. S. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-12457-1_37 · Cited by 26
Effects of Incretin Therapy on Skeletal Health in Type 2 Diabetes—A Systematic Review
Viggers, R., Rasmussen, N. H., & Vestergaard, P. (2023) · JBMR Plus · doi:10.1002/jbm4.10817 · Cited by 29
Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists
Jensen, E., Israelsen, M. E., & Krag, A. A. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000561 · Cited by 25
“[16] In the skeletal muscles, the presence of GLP-1 receptors is still debated.”
BackgroundKeivanlou, M., Amini‐Salehi, E., Hassanipour, S., Zare, R., Mohammadi‐Vajari, E., Hashemi, M., Salari, A., & Porteghali, P. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998284844240102110559 · Cited by 22
Scavo, M. P., Lisco, G., Depalo, N., Rizzi, F. R., Volpe, S., Arrè, V., Carrieri, L., Notarnicola, M., Nunzio, V. D., Curri, M. L., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031493 · Cited by 19
“These effects are mediated by GLP-1 binding to islet GLP-1 receptors [11].”
BackgroundProglucagon-derived peptides: human physiology and therapeutic potential
Gasbjerg, L. S., Nielsen, C. K., Suppli, M. P., Grøndahl, M. F. G., Holst, J. J., Knop, F. K., Jeppesen, P. B., & Lund, A. (2025) · Physiological Reviews · doi:10.1152/physrev.00057.2024 · Cited by 22
Maurer, L., Mai, K., Krude, H., Haynes, J., Weygandt, M., & Spranger, J. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.08.014 · Cited by 21
Reed, J., Bain, S. C., & Kanamarlapudi, V. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s415934 · Cited by 24
“11,227,228 Islet alpha-cell GLP-1R knockout mice were unable to inhibit glucagon secretion at high glucose levels, and surprisingly, these mice exhibited reduced glucagon secretion during low glucose conditions.”
The functional importance of the cellular and extracellular composition of the islets of Langerhans
Wieland, F. C., van Blitterswijk, C., van Apeldoorn, A. A., & LaPointe, V. L. S. (2021) · Journal of Immunology and Regenerative Medicine · doi:10.1016/j.regen.2021.100048 · Cited by 25
Beta Cell Imaging—From Pre-Clinical Validation to First in Man Testing
Demine, S., Schulte, M. I., Territo, P. R., & Eizirik, D. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197274 · Cited by 15
“Indeed, this receptor was found expressed in alpha cells [65] and recent studies using super-resolution microscopy and fluorescent exendin-4 derivatives confirmed that GLP-1R is present in at least 5% of alpha cell population [66].”
BackgroundModel, J. F. A., Lima, M. V., Ohlweiler, R., Sarapio, E., Vogt, É. L., Rocha, D. S., de Souza, S. K., & Vinagre, A. S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119586 · Cited by 15
The Current State of Beta-Cell-Mass PET Imaging for Diabetes Research and Therapies
Cheung, P., & Eriksson, O. (2021) · Biomedicines · doi:10.3390/biomedicines9121824 · Cited by 13
A famsin-glucagon axis mediates glucose homeostasis
Long, A., Wang, Y., Guo, Y., Hong, J., Ning, G., Meng, Z., Wang, Y., & Wang, Y. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.11.008 · Cited by 12
Zhang, J., Sanan, S., Csanalosi, M., Zheng, C., & Pfeiffer, A. F. H. (2025) · Endocrinology · doi:10.1210/endocr/bqaf130 · Cited by 15
Glucagon-Like Peptide 1 (GLP-1) Action on Hypothalamic Feeding Circuits
Hwang, E., Portillo, B., & Williams, K. W. (2025) · Endocrinology · doi:10.1210/endocr/bqaf125 · Cited by 10
Parajuli, K., Zhang, Y.-Q., Cao, A., Wang, H.-J., Fonseca, V., & Wu, H. (2020) · Cell Transplantation · doi:10.1177/0963689720958655 · Cited by 10
Self-citationGuida, C., MIRANDA, C. A., Asterholm, I. W., Basco, D., Benrick, A., Chanclón, B., Chibalina, M. V., Harris, M., Kellard, J. A., McCulloch, L. J., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/785667 · Cited by 13
Exploring the multifaceted roles of GLP-1 receptor agonists; a comprehensive review
Hammad, B. F., Zafar, N., Ullah, M., Faisal, S. J., Iftikhar, F., Waheed, H., Muzaffar, M. W., Ahmed, K., Ashraf, F., Zahid, K., et al. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1590530 · Cited by 14
Ehsasatvatan, M., & Kohnehrouz, B. B. (2023) · Scientific Reports · doi:10.1038/s41598-023-45185-1 · Cited by 9
Active targeting of type 1 diabetes therapies to pancreatic beta cells using nanocarriers
Collins, J., & Farnsworth, N. L. (2025) · Diabetologia · doi:10.1007/s00125-024-06356-5 · Cited by 11
“Furthermore, cells in the gut, brain and heart have recently been shown to express GLP-1Rs, with some evidence also supporting expression of GLP-1Rs in islet alpha cells, which may lead to off-target accumulation [99, 100].”
Dong, Y., Shi, Y., Li, G., Wang, M., Leng, L., & Li, Q. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.01.94 · Cited by 8
Engineering Supramolecular Nanofiber Depots from a Glucagon-Like Peptide-1 Therapeutic
Chen, W., Xian, S., Webber, B., DeWolf, E. L., Schmidt, C. R., Kilmer, R., Liu, D., Power, E. M., & Webber, M. J. (2024) · ACS Nano · doi:10.1021/acsnano.4c10248 · Cited by 8
Ruiz-Pino, A., Goncalves-Ramírez, A., Jiménez-Palomares, M., Merino, B., Castellano-Muñoz, M., Vettorazzi, J. F., Rafacho, A., Marroquí, L., Nadal, Á., Alonso‐Magdalena, P., et al. (2024) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-024-03045-5 · Cited by 11
“Like-wise, considering that GLP-1 suppresses glucagon secretion in the pancreatic α-cell [61], the concomitance of augmented plasma glucagon and GLP-1 levels in fed state indicate that this signaling pathway might be compromised in db/db mice.”
Patel, R., Kokori, E., Olatunji, G. D., Adejumo, F. A., Ukah, J. D., Babalola, A. E., Ndakotsu, A., Abraham, I. C., & Aderinto, N. (2025) · Current Heart Failure Reports · doi:10.1007/s11897-025-00704-1 · Cited by 10
“IL-6 plays a pivotal role in systemic inflammation by promoting oxidative stress and myocardial hypertrophy [33].”
Lokman, E. F., Bugam, S. H., Ibrahim, A. S., Yunus, N., Mansor, F., Balasubramaniam, V. R. M. T., Mohamad, K. M., Lazim, R. M., & Seruji, A. Z. R. A. (2023) · Nutrition and Health · doi:10.1177/02601060231152060 · Cited by 6
“GLP-1 plays an important role for BG regulation since the hormone improves insulin level and reduces glucagon (Zhang et al., 2019).”
Grau‐Bové, C., Ginés, I., Beltrán‐Debón, R., Terra, X., Blay, M., Pinent, M., & Ardèvol, A. (2021) · Nutrients · doi:10.3390/nu13041084 · Cited by 8
“[23], GLP-1R regulation is much more important for glucagon than for insulin.”
BackgroundKang, S., Kim, N. H., & Yu, Y. G. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.10.071 · Cited by 6
Güldan, M., Özbek, L., Abdel‐Rahman, S. M., Narin, A. E., Orak, H. İ., Goren, H. K., Afşar, B., Rossing, P. R., & Kanbay, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70019 · Cited by 7
“57 In T2DM, chronic hyperglycaemia impairs insulin secretion and downregulates GLP-1R expression, diminishing β -cell function.”
Siewe, N., & Friedman, A. (2024) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2024.111756 · Cited by 8
The Role of Insulin Resistance in Cardiorenal Metabolic Syndrome
Xiao, J., Song, W. L., Huang, Y., He, X., Weng, Y., & Yu, H. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001048 · Cited by 5
Targeting cardiometabolic risk in type 1 diabetes through incretin physiology
Frampton, R., HOCKING, S. L., SNAITH, J. R., & Greenfield, J. R. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.06.004 · Cited by 4
Li, H.-Y., Lip, G. Y. H., Chan, T.-K., Yiu, K. H., Tse, H., Martin, C. A., & Chan, Y.-H. W. (2026) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-026-02297-8 · Cited by 6
“GLP-1 RA may prevent AF by reducing atrial remodelling [39 ] through enhanced myocardial metabolism, sta - bilised blood glucose, and regulating the RAAS in animal studies [40, 41 ].”
The therapeutic approach to cardiovascular–kidney–metabolic syndrome
Rangaswami, J., Lo, K. B., & Ndumele, C. E. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01109-6 · Cited by 4
Xiong, S., Liu, Q., Zhou, S., & Xiao, Y. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e22430 · Cited by 3
Hadid, S. A., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000940 · Cited by 3
Antidiabetic triterpenoids from the leaves of Paeonia suffruticosa and Paeonia delavayi
Huang, Q., Pan, Y., Wu, S., Huang, X., Jing Hua, H. U., Ma, Y., Zhang, X., & Geng, C. (2022) · Phytochemistry Letters · doi:10.1016/j.phytol.2022.02.009 · Cited by 3
Peart, L. A., Draper, M., & Tarasov, A. I. (2024) · Peptides · doi:10.1016/j.peptides.2024.171243 · Cited by 5
Grigore, M., Grigore, A.-M., Ruxandra-Elena, M.-G., Verde, I., Uscoiu, G., Nicolae, C., Balahura, A.-M., & Ilieşiu, A. (2025) · Life · doi:10.3390/life16010016 · Cited by 3
“GLP-1 RAs are widely used in patients with type 2 DM, primarily for their antihyperglycemic effects, and secondarily for cardiovascular benefits, including reductions in blood pressure and total cholesterol [61].”
InfluentialPharmacological interactions between asthma and T2DM therapies: clinical and metabolic implications
Matera, M. G., Page, C. P., Calzetta, L., Rogliani, P., & Cazzola, M. (2026) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2026.2632668 · Cited by 3
“GLP-1 also suppresses glucagon, delays gastric emptying, and promotes satiety, thereby contributing to glycemic control and weight regulation [138].”
Incretin-Based Therapies: A Novel Pathway in Addiction Treatment
Rosiejka, D., Joanna, M., Marcickiewicz, J., Bogdańska, A., Błażejewska, W., & Szulińska, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15041613 · Cited by 2
“In α -cells, GLP-1RA activates a similar cAMP-induced pathway; however, this mechanism inhibits glucagon release [39].”
Glucagon-like peptide-1 mimotopes screened from an Fv-antibody library
Bae, H. E., Choi, D., Sung, J. S., Lee, H. W., Kang, M., Jose, J., Lee, M., & Pyun, J. (2026) · Journal of Materials Chemistry B · doi:10.1039/d5tb02128f · Cited by 3
Xu, L., Hu, R., Jois, S. V., & Zhang, L. (2023) · PeerJ · doi:10.7717/peerj.15705 · Cited by 2
“Another research also supported our finding, when the glucose level is high, GLP-1R in α -cell exert the function of inhibiting glucagon secretion ( Zhang et al., 2019 ) which can prevent the increase of glucose level.”
Teitelman, G. (2024) · Journal of Histochemistry & Cytochemistry · doi:10.1369/00221554241274879 · Cited by 3
Alghamdi, F. A., Alshegifi, H., Alhuthayli, R., Helal, T., Huwait, T. A., Alharbi, T., Akbar, A. F., Alshehri, W., & Alsheikh, S. (2024) · Cureus · doi:10.7759/cureus.74345 · Cited by 3
Dysbiosis–epigenetics–immune system interaction and ageing health problems
Eshkoor, S. A., & Fanijavadi, S. (2024) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001921 · Cited by 2
Lokman, E. F., Bugam, S. H., Ibrahim, A. S., Yunus, N., Mansor, F., Balasubramaniam, V. R. M. T., Mohamad, K. M., Lazim, R. M., & Seruji, A. Z. R. A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.26.501535 · Cited by 2
Houssarini, J. A., Brnabic, A. J. M., & Obaid, M. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01184-x · Cited by 1
Glucagon and the metabolic syndrome
Welch, A., & Vella, A. V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00011-6 · Cited by 2
Srour, L., Ismail, J., Njeim, R., & Eid, A. A. (2024) · Oxidative stress in applied basic research and clinical practice · doi:10.1007/978-3-031-62131-4_8 · Cited by 2
Ketotic Hypoglycaemia Following Sleeve Gastrectomy
He, J., Phillips, L. K., Nisbet, J. C., & Morton, A. (2025) · Clinical Endocrinology · doi:10.1111/cen.15232 · Cited by 1
Glucagon-like Peptide-1 Agonists and Exercise for Weight Reduction: A Review of Current Evidence
Owaidat, J. F., Zuaiter, S., Daseh, A. I., Nemrawi, F. A. A., Abu‐Jeyyab, M., & Al-Jafari, M. (2025) · JAP Academy Journal · doi:10.4103/japaj.japaj_5_24 · Cited by 1
Prihanti, G. S., Illahika, A. P., & Lestari, N. D. (2026) · Journal of Taibah University Medical Sciences · doi:10.1016/j.jtumed.2026.05.008 · Cited by 1
“8,9 GLP-1 is also able to promote β -cell survival via various interconnected molecular mechanisms, mainly through binding to its receptor, which then activates further downstream signaling.”
Ferreira, B., Lemos, I., Mendes, C., Chumbinho, B., SILVA, F. A. B. N. D., Pereira, D., Vigia, E., Gonçalves, L. G., Figueiredo, A., Cavaco, D., et al. (2025) · Molecules · doi:10.3390/molecules30132736 · Cited by 1
“Considering the role of GLP-1R in glucose homeostasis [29,72,73], its diminished expression in pNETs could indicate a dysregulation in the insulin–glucagon axis [28].”
GLP1-Receptor Agonists in Diabetes: Drugs, General Effects, and Cardiovascular Impact
Breder, I. S. S., & Sposito, A. C. (2020) · Springer eBooks · doi:10.1007/978-3-030-53370-0_51 · Cited by 1
Small molecule glucagon release inhibitors with activity in human islets
Kalwat, M. A., Rodrigues-dos-Santos, K., Binns, D. D., Wei, S., Zhou, A., Evans, M. R., Posner, B. A., Roth, M. G., & Cobb, M. H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1114799 · Cited by 1
Adding GABA to Insulin Leads to New era in Type 1 Diabetes Management
Younis, M. (2022) · Clinical Cardiology and Cardiovascular Interventions · doi:10.31579/2641-0419/262
Human beta cells become dysfunctional prior to type 1 diabetes diagnosisPreprint
Teitelman, G. (2024) · Research Square · doi:10.21203/rs.3.rs-5285252/v1
Birth of a Microdomain: Can Glucose Act as a Metabolic Switch?
Pallavi, A., & Gandasi, N. R. (2025) · DNA and Cell Biology · doi:10.1177/10445498251391706
“Secretagogue like glucose stimulates insulin secretion, whereas GLP-1 can inhibit glucagon secretion (Gandasi and Rorsman, 2024; Wendt and Eliasson, 2022; Zhang et al., 2019), although with respect to glucagon remain unclear (Gandasi and Rorsman, 2024).”
Teitelman, G. (2025) · Journal of Histochemistry & Cytochemistry · doi:10.1369/00221554251387770
Metadata
- Authors
- Zhang, Y., Parajuli, K. R., Fava, G. E., Gupta, R., Xu, W., Nguyen, L. U., Zakaria, A. F., Fonseca, V. A., Wang, H., Mauvais-Jarvis, F., Sloop, K. W., & Wu, H.
- Affiliations
- Tulane University (US)
- Medical University of South Carolina (US)
- Section of Endocrinology, Department of Medicine, Tulane University Health Science Center, New Orleans, LA
- Eli Lilly (United States) (US)
- Corresponding author
- Wu, Hongju
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2018-11-02
- Volume
- 68
- Issue
- 1
- Pages
- 34-44
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC6302540
- OpenAlex
- W2899183711
- Semantic Scholar
- ac8cb7167621574489ce0bd5c237f46e94084811
- Cited by
- 104
- References
- 43
- Citations by year
- 2026: 10 · 2025: 20 · 2024: 17 · 2023: 15 · 2022: 5 · 2021: 16 · 2020: 14 · 2019: 7
- FWCI
- 6.86
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Susan Harling Robinson Fellowship in Diabetes research
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-081463, DK-107412, R01-DK-074970, DK-107444)
- U.S. Department of Veterans Affairs VA Merit Review Award (BX003725)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- GLP-1 receptor, glucagon secretion, alpha cells, bidirectional regulation, impaired glucose tolerance, hypoglycemia, islet function, beta-cell function, glucose metabolism
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Animals, Female, Flow Cytometry, Glucagon, Glucose, Glucose Tolerance Test, Immunohistochemistry, Mice, Knockout, Reverse Transcriptase Polymerase Chain Reaction, Glucagon-Secreting Cells, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.